Cerebral embolic protection devices reduced ischemic stroke incidence from 4.1% to 1.4% in patients undergoing transcatheter aortic valve replacement, representing a 66% relative risk reduction in this 1,101-patient retrospective study. The analysis compared 809 patients who received cerebral protection with 292 who did not during the minimally invasive heart valve procedure. This finding addresses a critical complication of TAVR, where debris from the calcified valve can travel to the brain during the procedure. The protective devices act as filters to capture embolic material before it reaches cerebral circulation. While TAVR has revolutionized treatment for aortic stenosis in elderly patients who are too high-risk for open surgery, stroke remains a feared complication that can devastate quality of life. The 66% stroke reduction could significantly improve the risk-benefit profile of this increasingly common procedure, potentially expanding its use to lower-risk patients. However, this single-center retrospective analysis has inherent limitations including selection bias and confounding variables. The study period spans from 2017-2025, and as a preprint awaiting peer review, these results require validation through randomized controlled trials before definitively establishing cerebral protection as standard care.